Results 71 to 80 of about 94,936 (269)
De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley +1 more source
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau +7 more
wiley +1 more source
ABA enhances the apoptotic effect of docetaxel in the multidrug-resistant DU145 prostate cancer cell line [PDF]
This study aimed to induce drug resistance in DU145 prostate cancer cells by exposing them to docetaxel and mitoxantrone, and to examine the effects of combining docetaxel and abscisic acid (ABA).
Şumnulu Deniz, Doğanlar Zeynep Banu
doaj +1 more source
Cytotoxic effects of docetaxel (DTX), docetaxel + ESWs (DTX ESWs), docetaxel-NBs (DTX NB), and docetaxel-loaded NBs + ESWs (DTX NB ESWs), in PC3 (panel A) and DU145 (panel B) cells.
Paolo Gontero (3534284) +12 more
core +1 more source
ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia +35 more
wiley +1 more source
Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting [PDF]
Introduction: The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castration- resistant prostate cancer (MCRPC) in rural Nordland County, Norway.
Nieder, Carsten +7 more
core +1 more source
ABSTRACT Esophageal adenocarcinoma (EAC) exhibits marked male predominance with male‐to‐female ratios reaching 8.5:1, yet the molecular basis underlying this sex disparity remains poorly characterized. We analyzed 92 EAC specimens using mass spectrometry–based proteomics, comprising 47 female and 45 male tumors from treatment‐naïve patients ...
Alexander Quaas +8 more
wiley +1 more source
Docetaxel‐based chemotherapy has generally been considered as one of the effective treatments for castration‐resistant prostate cancer (PCa). However, clinical treatment with docetaxel often encounters a number of undesirable effects, including drug ...
Yeong‐Shiau Pu +10 more
doaj +1 more source
How nanotechnology can enhance docetaxel therapy
Li Zhang, Na ZhangSchool of Pharmaceutical Science, Shandong University, Shandong Province, People's Republic of ChinaAbstract: Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water ...
Zhang N, Zhang L
core
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei +5 more
wiley +1 more source

